Toronto, Canada-based Winterlight Labs, Inc, (Winterlight) recently announced it has entered a partnership with Janssen Pharmaceuticals (Janssen) to develop a digital biomarker for the diagnosis of early stage Alzheimer’s Disease (AD). Janssen, which is part of Johnson & Johnson Innovation LLC, is a Belgium-based pharmaceutical company that conducts research and development activities related to a wide range of medical disorders.
Currently, Winterlight’s technology reports a 91% accuracy rating for distinguishing Alzheimer’s from healthy aging. It accomplishes this by utilizing AI to create digital biomarkers to evaluate a person’s speech and language. Through its collaboration with Janssen, the two organizations will seek to better identify AD in individuals before symptoms begin to emerge. Winterlight leadership states that by doing so, early intervention methods can be implemented that extend and improve the quality of life for individuals with the neuro-degenerative disease.
Winterlight Labs’ mission is to create faster and more objective way to measure neurological and psychiatric illness through speech using artificial intelligence (AI). Winterlight’s fully automated and compliant platform is currently being used by pharmaceutical companies to detect dementia, measure response to therapy, and track symptoms remotely.
This was reported by Cision PR Newswire on January 7, 2019.
Contact Information: Winterlight Labs, MaRS DD, West Tower, 661 Unviersity Avenue, Suite 1300, Toronto, Ontario M5G 0B7; Website: www.winterlightlabs.com
Contact Information: Janssen Pharmaceuticals, 1000 U.S. Route 202 South, Raritan, New Jersey 08869; (908) 722-5393; Website: www.janssen.com